Becton, Dickinson and Company (NYSE:BDX) Shares Sold by Hahn Capital Management LLC

Hahn Capital Management LLC cut its holdings in Becton, Dickinson and Company (NYSE:BDX) by 33.6% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 20,723 shares of the medical instruments supplier’s stock after selling 10,489 shares during the period. Becton, Dickinson and Company makes up about 3.2% of Hahn Capital Management LLC’s portfolio, making the stock its 19th largest holding. Hahn Capital Management LLC’s holdings in Becton, Dickinson and Company were worth $4,996,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of BDX. Nordea Investment Management AB boosted its holdings in shares of Becton, Dickinson and Company by 277.3% in the 1st quarter. Nordea Investment Management AB now owns 1,936,654 shares of the medical instruments supplier’s stock valued at $478,295,000 after buying an additional 1,423,353 shares during the period. PineStone Asset Management Inc. boosted its stake in Becton, Dickinson and Company by 141.6% during the 2nd quarter. PineStone Asset Management Inc. now owns 1,345,873 shares of the medical instruments supplier’s stock valued at $314,544,000 after purchasing an additional 788,735 shares during the period. M&G Plc acquired a new position in Becton, Dickinson and Company during the 1st quarter valued at about $173,692,000. First Eagle Investment Management LLC boosted its stake in Becton, Dickinson and Company by 32.5% during the 2nd quarter. First Eagle Investment Management LLC now owns 2,803,255 shares of the medical instruments supplier’s stock valued at $655,149,000 after purchasing an additional 688,296 shares during the period. Finally, Bank of New York Mellon Corp boosted its stake in Becton, Dickinson and Company by 8.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 4,412,163 shares of the medical instruments supplier’s stock valued at $1,031,167,000 after purchasing an additional 346,720 shares during the period. 86.97% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

BDX has been the subject of a number of analyst reports. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and boosted their target price for the company from $255.00 to $275.00 in a research note on Tuesday, October 1st. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Evercore ISI boosted their target price on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Stifel Nicolaus boosted their target price on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Finally, Raymond James reduced their price target on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research note on Friday, August 2nd. Nine analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $282.63.

Becton, Dickinson and Company Trading Down 0.8 %

Shares of NYSE:BDX opened at $238.62 on Friday. The company has a 50 day moving average of $237.33 and a 200-day moving average of $235.16. The firm has a market cap of $68.96 billion, a P/E ratio of 52.56, a P/E/G ratio of 1.79 and a beta of 0.42. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $262.23. The company has a current ratio of 1.85, a quick ratio of 1.36 and a debt-to-equity ratio of 0.70.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.31 by $0.19. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The firm had revenue of $4.99 billion for the quarter, compared to analyst estimates of $5.08 billion. During the same quarter in the previous year, the business posted $2.96 earnings per share. The firm’s quarterly revenue was up 2.3% compared to the same quarter last year. As a group, analysts anticipate that Becton, Dickinson and Company will post 13.11 earnings per share for the current fiscal year.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.